Hairy cell leukemia – immunotargets and therapies

References

• FoucarKFaliniBCatovskyDSteinHHairy cell leukaemiaWHO Classification of Tumours of the Haematopoietic and Lymphoid TissuesSwerdlowSHCampoEHarrisNLLyon, FranceIARC Press, Lyon2008
   Google Scholar
• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin201363113023335087
   PubMed Web of Science ®Google Scholar
• FerlayJSteliarova-FoucherELortet-TieulentJCancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012Eur J Cancer2013491374140323485231
   PubMed Web of Science ®Google Scholar
• BouroncleBAWisemanBKDoanCALeukemic reticuloendotheliosisBlood19581360963013560561
   PubMed Web of Science ®Google Scholar
• SchrekRDonnellyWJ“Hairy” cells in blood in lymphoreticular neoplastic disease and “flagellated” cells of normal lymph nodesBlood1966271992115322749
   PubMed Web of Science ®Google Scholar
• ElseMDeardenCEMatutesELong-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosisBr J Haematol200914573374019344416
   PubMed Web of Science ®Google Scholar
• TiacciETrifonovVSchiavoniGBRAF mutations in hairy-cell leukaemiaN Engl J Med20113642305231521663470
   PubMed Web of Science ®Google Scholar
• BoydEMBenchAJvan’t VeerHigh resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignanciesBr J Haematol201115560961221910720
   PubMed Web of Science ®Google Scholar
• KreitmanRJHairy cell leukaemia – new genes, new targetsCurr Hematol Malig Rep2013818419523892906
   PubMed Web of Science ®Google Scholar
• SainatiLMatutesEMulliganSA variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patientsBlood1990761571622364167
   PubMed Web of Science ®Google Scholar
• MatutesEWotherspoonABrito-BabapulleVCatovskyDThe natural history and clinico-pathological features of the variant form of hairy cell leukemiaLeukemia20011518418611243388
   PubMed Web of Science ®Google Scholar
• RobakTHairy-cell leukaemia variant: recent view on diagnosis, biology and treatmentCancer Treat Rev20113731020558005
   PubMed Web of Science ®Google Scholar
• AronsESuntumTStetler-StevensonMKreitmanRJVH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapyBlood20091144687469519745070
   PubMed Web of Science ®Google Scholar
• XiLAronsENavarroWBoth variant and IGHV4-34- expressing hairy cell leukemia lack the BRAF V600E mutationBlood20121193330333222210875
   PubMed Web of Science ®Google Scholar
• QuesadaJRReubenJManningJTHershEMGuttermanJUAlpha interferon for induction of remission in hairy-cell leukemiaN Engl J Med198431015186689734
   PubMed Web of Science ®Google Scholar
• GreverMKopeckyKFoucarMKRandomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an Intergroup studyJ Clin Oncol1995139749827707126
   PubMed Web of Science ®Google Scholar
• ChesonBDSorensenJMVenaDATreatment of hairy cell leukemia with 2- chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patientsJ Clin Oncol199816300730159738569
   PubMed Web of Science ®Google Scholar
• PiroLDCarreraCJCarsonDABeutlerELasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosineN Engl J Med1990322111711211969613
   PubMed Web of Science ®Google Scholar
• RobakTJamroziakKGora-TyborJCladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trialBlood20071093672367517209059
   PubMed Web of Science ®Google Scholar
• GoodmanGRBurianCKoziolJASavenAExtended follow-up of patients with hairy cell leukemia after treatment with cladribineJ Clin Oncol20032189189612610190
   PubMed Web of Science ®Google Scholar
• DeardenCEMatutesEHilditchBLSwansburyGJCatovskyDLong-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribineBr J Haematol199910651551910460614
   PubMed Web of Science ®Google Scholar
• KrautEHNeffJCBouroncleBAGochnourDGreverMRImmunosuppressive effects of pentostatinJ Clin Oncol199088488552332771
   PubMed Web of Science ®Google Scholar
• SavenAPiroLD2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignanciesAnn Intern Med19941207847917908507
   PubMed Web of Science ®Google Scholar
• TadmorTPurine analog toxicity in patients with hairy cell leukemiaLeuk Lymphoma201152Suppl 2384221463124
   PubMed Web of Science ®Google Scholar
• ChesonBDVenaDAFossFMSorensenJMNeurotoxicity of purine analogs: a reviewJ Clin Oncol199412221622287931492
   PubMed Web of Science ®Google Scholar
• BeersSAChanCHFrenchRRCraggMSGlennieMJCD20 as a target for therapeutic type I and II monoclonal antibodiesSemin Hematol20104710711420350657
   PubMed Web of Science ®Google Scholar
• GinaldiLDe MartinisMMatutesELevels of expression of CD19 and CD20 in chronic B cell leukaemiasJ Clin Pathol1998513643699708202
   PubMed Web of Science ®Google Scholar
• ReffMECarnerKChambersKSDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood1994834354457506951
   PubMed Web of Science ®Google Scholar
• AviviIStroopinskyDKatzTAnti-CD20 monoclonal antibodies: beyond B-cellsBlood Rev20132721722323953071
   PubMed Web of Science ®Google Scholar
• CoiffierBLepageEBriereJCHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphomaN Engl J Med200234623524211807147
   PubMed Web of Science ®Google Scholar
• DotanEAggarwalCSmithMRImpact of rituximab (rituxan) on the treatment of B-cell non-Hodgkin’s lymphomaP T20103514815720442809
   PubMedGoogle Scholar
• HagbergHLundholmLRituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemiaBr J Haematol200111560961111736943
   PubMed Web of Science ®Google Scholar
• ThomasDAO’BrienSBueso-RamosCRituximab in relapsed or refractory hairy cell leukemiaBlood20031023906391112816862
   PubMed Web of Science ®Google Scholar
• NievaJBethelKSavenAPhase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemiaBlood200310281081312663446
   PubMed Web of Science ®Google Scholar
• ElseMDeardenCEMatutesERituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrenceLeuk Lymphoma201152Suppl 2757821504288
   PubMed Web of Science ®Google Scholar
• JonesGParry-JonesNWilkinsBElseMCatovskyDBritish Committee for Standards in HaematologyRevised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variantBr J Haematol201215618619522111844
   PubMed Web of Science ®Google Scholar
• RavandiFO’BrienSJorgensenJPhase 2 study of cladribine followed by rituximab in patients with hairy cell leukemiaBlood20111183818382321821712
   PubMed Web of Science ®Google Scholar
• KantarjianHMSchachnerJKeatingMJFludarabine therapy in hairy cell leukemiaCancer199167129112931991291
   PubMed Web of Science ®Google Scholar
• KrautEHChunHGFludarabine phosphate in refractory hairy cell leukemiaAm J Hematol19913759601708945
   PubMed Web of Science ®Google Scholar
• GerrieASZypchenLNConnorsJMFludarabine and rituximab for relapsed or refractory hairy cell leukemiaBlood20121191988199122223825
   PubMed Web of Science ®Google Scholar
• NaratSGandlaJDoganAMehtaASuccessful treatment of hairy cell leukemia variant with rituximabLeuk Lymphoma2005461229123216085567
   PubMed Web of Science ®Google Scholar
• QuachHJanuszewiczHWestermanDComplete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximabHaematologica200590SupplECR2616266917
   PubMedGoogle Scholar
• Hadzi-PecovaLStojanovikAPetrusevskaGPanovskaIRituximab in the treatment of the variant of hairy cell leukaemia: a case reportPrilozi20082935536019259059
   PubMedGoogle Scholar
• QuigleyMMBethelKJSharpeRWSavenACD52 expression in hairy cell leukemiaAm J Hematol20037422722314635201
   PubMed Web of Science ®Google Scholar
• RodigSJAbramsonJSPinkusGSHeterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)Clin Cancer Res2006127174717917145843
   PubMed Web of Science ®Google Scholar
• FietzTRiegerKSchmittelAThielEKnaufWAlemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatmentHematol J2004545145215448675
   PubMedGoogle Scholar
• SasakiMSugimotoKMoriTKarasawaKOshimiKEffective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumabActa Haematol2008119485318259114
   PubMed Web of Science ®Google Scholar
• TelekBBatárPUdvardyMSuccessful alemtuzumab treatment of a patient with atypical hairy cell leukaemia variantOrv Hetil200714818051907 Hungarian17872336
   PubMedGoogle Scholar
• CarrollSFCollierRJActive site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxinJ Biol Chem1987262870787112885323
   PubMed Web of Science ®Google Scholar
• Van NessBGHowardJBBodleyJWADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis productsJ Biol Chem198025510717107207000782
   PubMed Web of Science ®Google Scholar
• KreitmanRJWilsonWHWhiteJDPhase I trial of recombinant immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignanciesJ Clin Oncol2000181614163610764421
   PubMed Web of Science ®Google Scholar
• National Cancer InstituteLMB-2 to treat hairy cell leukemia Available from: http://clinicaltrials.gov/show/NCT00321555Accessed May 13, 2014
   Google Scholar
• JasperGAArunIVenzonDVariables affecting the quantitation of CD22 in neoplastic B cellsCytometry B Clin Cytom201180839020872890
   PubMed Web of Science ®Google Scholar
• BabusikovaOTomovaAKusendaJGyarfasJFlow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatmentNeoplasma20014835035711845978
   PubMed Web of Science ®Google Scholar
• CordoneIAnninoLMasiSDiagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemiaJ Clin Pathol1995489559608537498
   PubMed Web of Science ®Google Scholar
• StoddartAJacksonAPBrodskyFMPlasticity of B cell receptor internalization upon conditional depletion of clathrinMol Biol Cell2005162339234815716350
   PubMed Web of Science ®Google Scholar
• KreitmanRJSquiresDRStetler-StevensonMPhase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignanciesJ Clin Oncol2005236719672916061911
   PubMed Web of Science ®Google Scholar
• KreitmanRJStetler-StevensonMMarguliesIPhase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemiaJ Clin Oncol2009272983299019414673
   PubMed Web of Science ®Google Scholar
• SalvatoreGBeersRMarguliesIKreitmanRJPastanIImproved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage displayClin Cancer Res20028995100211948105
   PubMed Web of Science ®Google Scholar
• AldersonRFKreitmanRJChenTCAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignanciesClin Cancer Res20091583283919188153
   PubMed Web of Science ®Google Scholar
• KreitmanRJTallmanMSRobakTPhase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemiaJ Clin Oncol2012301822182822355053
   PubMed Web of Science ®Google Scholar
• SalaEMologniLTruffaSGaetanoCBollagGEGambacorti-PasseriniCBRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cellsMol Cancer Res2008675175918458053
   PubMed Web of Science ®Google Scholar
• FlahertyKPhase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. Abstract presented at the 45th annual meeting of the American Society of Clinical Oncology, May 29 to June 2, 2009, Orlando, FL, USAJ Clin Oncol20002715 Suppl Abstr 9000
   Google Scholar
• FlahertyKTPuzanovIKimKBInhibition of mutated, activated BRAF in metastatic melanomaN Engl J Med201036380981920818844
   PubMed Web of Science ®Google Scholar
• DietrichSGlimmHAndrulisMvon KalleCHoADZenzTBRAF inhibition in refractory hairy-cell leukemiaN Engl J Med20123662038204022621641
   PubMed Web of Science ®Google Scholar
• DietrichSHülleinJHundemerMContinued response off treatment after BRAF inhibition in refractory hairy cell leukemiaJ Clin Oncol201331e300e30323690412
   PubMed Web of Science ®Google Scholar
• FollowsGASimsHBloxhamDMRapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenibBr J Haematol201316115015323278307
   PubMed Web of Science ®Google Scholar
• PeyradeFReDGinetCLow-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutationHaematologica201398e20e2223300174
   PubMed Web of Science ®Google Scholar
• MunozJSchletteEKurzrockRRapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutationJ Clin Oncol201331e351e35223733763
   PubMed Web of Science ®Google Scholar
• DavisRENgoVNLenzGChronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature2010463889220054396
   PubMed Web of Science ®Google Scholar
• HermanSEGordonALHertleinEBruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Blood20111176287629621422473
   PubMed Web of Science ®Google Scholar
• KozakiRYoshizawaTYashuhiroTDevelopment of a Bruton’s tyrosine kinase (Btk) inhibitor – ONO-WG-307, a potential treatment for B-cell malignanciesCancer Res201272 Abstr 857
   Web of Science ®Google Scholar
• UckunFDibirdikISarkissianAQaziSIn vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton’s tyrosine kinase and polo-like kinases, against human leukemic B-cell precursorsArzneimittelforschung20116125225921650085
   PubMed Web of Science ®Google Scholar
• HantschelORixUSchmidtUThe Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinibProc Natl Acad Sci U S A2007104132831328817684099
   PubMed Web of Science ®Google Scholar
• AmreinPCAttarECTakvorianTPhase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemiaClin Cancer Res2011172977298621402714
   PubMed Web of Science ®Google Scholar
• EvansEKTesterRAslanianSInhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humansJ Pharmacol Exp Ther201334621922823709115
   PubMed Web of Science ®Google Scholar
• AalipourAAdvaniRHBruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomasBr J Haematol201316343644324111579
   PubMed Web of Science ®Google Scholar
• ChandranRGardinerSKSmithSDSpurgeonSEImproved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factorsBr J Haematol201316340740923889044
   PubMed Web of Science ®Google Scholar